Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America
Ver/
Descargar
(application/pdf: 456.6Kb)
(application/pdf: 456.6Kb)
Fecha
2019Autor(es)
Casas, Alberto
Bravo, Leny
Zavaleta, Jenny
Metadatos
Mostrar el registro completo del ítemResumen
Advances in high-throughput technologies and their involvement in the ‘omics’ of cancer have made possible the identification of hundreds of
biomarkers and the development of predictive and prognostic platforms that model the management of cancer from evidence-based medicine
to precision medicine. Latin America (LATAM) is a region characterised by fragmented healthcare, high rates of poverty and disparities to
access to a basic standard of care not only for cancer but also for other complex diseases. Patients from the public setting cannot afford tar-
geted therapy, the facilities offering genomic platforms are scarce and the use of high-precision radiotherapy is limited to few facilities. Despite
the fact that LATAM oncologists are well-trained in the use of genomic platforms and constantly participate in genomic projects, a medical prac-
tice based in precision oncology is a great challenge and frequently limited to private practice. In breast cancer, we are waiting for the results of
large basket trials to incorporate the detection of actionable mutations to select targeted treatments, in a similar way to the management of lung
cancer. On the other hand and paradoxically, in the ‘one fit is not for all’ era, clinical and genomic studies continue grouping our patients under
the single label ‘Latin American’ or ‘Hispanic’ despite the different ancestries and genomic backgrounds seen in the region. More regional cancer
genomic initiatives and public availability of this data are needed in order to develop more precise oncology in locally advanced breast cancer.
Palabras clave
Colecciones
El ítem tiene asociados los siguientes ficheros de licencia: